TAVO + C-X-C motif chemokine ligand 9

**TAVO + C-X-C motif chemokine ligand 9** is an investigational intratumoral gene therapy combination from OncoSec built on **TAVO** and a **DNA-encoded locally secreted CXCL9** component, delivered by **electroporation** into tumors. TAVO itself is tavokinogene telseplasmid, a plasmid encoding **interleukin-12**, which is designed to induce local IL-12 expression, stimulate IFN-gamma driven immune activation, increase tumor immunogenicity, and recruit effector T cells into the tumor microenvironment. The added **CXCL9** component is intended to amplify the **CXCR3/CXCL9 axis**, enhancing trafficking and retention of CXCR3-positive CD8-positive T cells in tumors and thereby strengthening systemic antitumor immunity and sensitization to checkpoint blockade. Available public information indicates this specific combination remained a **preclinical oncology program** rather than an approved medicine, with reported work focused on solid tumors and on converting immunologically cold tumors into inflamed tumors more responsive to immunotherapy.

Other names

tavokinogene telseplasmid + C-X-C motif chemokine ligand 9plasmid interleukin-12 + CXCL9IL-12 + CXCL9